Takeda Pharmaceutical Co 4502.T · JPY
Health Care · Pharmaceuticals · Tokyo Stock Exchange · 🇯🇵 Japan
6,673
+1.72%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Takeda Pharmaceutical Co
Its shares trade on Tokyo Stock Exchange under the ticker 4502.T. It has been listed since 16 May 1949. In the fiscal year to 31 March 2026, it reported revenue of ¥4.51trn and net income of ¥191.76bn. At that date it held total assets of ¥15.45trn and shareholders' equity of ¥7.77trn.
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 May 1949
- Employees
- 47,495
- Website
- takeda.com ↗
Leadership
Pay as last reported
- Mr. Masami IijimaChairman of Board of Directors, Independent Director¥43.0m
- Mr. Christophe WeberPresident, Chief Executive Officer, Representative Director, since 2014¥1.73bn
- Mr. Costa SaroukosChief Financial Officer, Director, since 2019¥676.0m
- Dr. Andrew PlumpPresident of Research & Development, Vice President of Subsidiary, Director, since 2015¥12.0m
- Mr. Olivier BohuonIndependent Director¥38.0m
- Mr. Jean-Luc ButelIndependent Director¥38.0m
- Mr. Ian ClarkIndependent Director, since 2019¥38.0m
- Mr. Yoshiaki FujimoriIndependent Director¥41.0m
- Dr. Steven GillisIndependent Director¥38.0m
- Mr. Koji HatsukawaIndependent Director¥43.0m
- Ms. Emiko HigashiIndependent Director¥43.0m
- Dr. John MaraganoreIndependent Director¥32.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 93
- Environment
- 99
- Social
- 99
- Governance
- 82
- Direct emissions (scope 1)
- 279,000 t
- Energy emissions (scope 2)
- 282,000 t
- Value chain emissions (scope 3)
- 3,953,000 t
- Women in the workforce
- 52%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Takeda Pharmaceutical Co Ltd possesses various strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong global presence with operations in multiple countries, which allows it to access diverse markets and benefit from global demand. Additionally, Takeda has a broad range of pharmaceutical products, including both prescription drugs and over-the-counter medications, enabling it to cater to a wide customer base. The company also boasts a robust research and development (R&D) pipeline, investing heavily in innovative solutions to address various diseases and medical conditions.
- Another notable strength of Takeda is its extensive partnerships and collaborations with other pharmaceutical companies and research institutions. This provides the company with access to cutting-edge technologies, as well as shared knowledge and resources. Furthermore, Takeda has a strong brand reputation built upon its commitment to delivering high-quality, reliable, and safe pharmaceutical products to consumers worldwide.
Weaknesses
- Despite its strengths, Takeda Pharmaceutical Co Ltd also faces certain weaknesses that it must address. One such weakness is the company's heavy reliance on a few key products for a significant portion of its revenue. This concentration poses a risk as any negative impact on those products could have a significant financial effect on Takeda. Moreover, Takeda operates in a highly competitive industry where pricing pressures and regulatory challenges may limit its growth opportunities.
- Another weakness lies in Takeda's historical focus on the Japanese market, which has limited its international market share compared to some of its global competitors. This dependency on the domestic market may hinder the company's ability to expand rapidly and diversify its revenue streams.
Opportunities
- Takeda Pharmaceutical Co Ltd can explore several opportunities to strengthen its position in the market and drive growth. Firstly, the increasing focus on personalized medicine and advancements in precision therapies present an opportunity for Takeda to leverage its R&D capabilities and develop targeted treatment options. Additionally, the growing aging population in many countries creates a demand for drugs related to age-related diseases and conditions, which Takeda can tap into.
- Furthermore, Takeda can capitalize on emerging markets, particularly in Asia and Latin America, where healthcare spending and access to pharmaceutical products are on the rise. By expanding its presence in these regions, the company can unlock new revenue streams and gain a competitive advantage over its peers. Moreover, digital healthcare advancements offer opportunities for Takeda to enhance its product offerings and develop innovative solutions for remote patient monitoring, telemedicine, and data analytics.
Threats
- Takeda Pharmaceutical Co Ltd faces various threats that may impact its business operations. One significant threat is the increasing regulatory scrutiny and requirements imposed on the pharmaceutical industry, which can lead to delays in product approvals and increased compliance costs. Additionally, Takeda operates in a constantly evolving patent landscape, where the expiration of patents for key drugs exposes the company to potential revenue loss from generic drug competition.
- Another threat is the risk of disruptions in the global supply chain, such as natural disasters or political uncertainties, which can disrupt Takeda's manufacturing processes and distribution networks. Furthermore, intense competition from both established pharmaceutical companies and emerging players poses a threat to Takeda's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.